Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada

by Vandana Singh, Benzinga Editor

September 20, 2021 1:46 PM | 1 min read |

Health Canada has given conditional approval to Incyte Corporation's INCY Pemazyre (pemigatinib) to treat cholangiocarcinoma.
Cholangiocarcinoma is a type of cancer that forms in the slender tubes (bile ducts) that carry the digestive fluid bile.
The approval covers adults with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
Pemazyre is a selective fibroblast growth factor receptor (FGFR) inhibitor.
The conditional approval is based on FIGHT-202 study data that resulted in an overall response rate (ORR) of 35.5% and a median duration of response of 9.1 months.
Related content: Benzinga's Full FDA Calendar.
Price Action: INCY stock is up 1.24% at $76.93 during the market session on the last check Monday.

Posted In: Biotech News Health Care FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.